Drug-Coated Balloon Catheters Market Report Scope & Overview:

The Drug-Coated Balloon Catheters Market was valued at USD 1.24 Billion in 2025 and is expected to reach USD 2.78 Billion by 2035, growing at a CAGR of 8.45% from 2026 to 2035.

The Drug-Coated Balloon Catheters Market is growing due to increasing incidence of coronary artery disease and peripheral arterial diseases, coupled with the increasing demand for minimally invasive non-stented revascularization therapy. Drug-coated balloon provides local delivery of anti-proliferative drugs, thus reducing restenosis without requiring permanent implantations. The increasing use of drug coated balloons in cases of in-stent restenosis, femoropopliteal lesions and complicated vascular cases will drive the market. Innovations such as coating with sirolimus and enhanced drug loading capacity along with increasing approvals by regulatory authorities have increased the applicability of the product. Other drivers include increasing number of catheterization lab procedures, artificial intelligence assisted imaging, and collaboration among the manufacturers.

In July 2025, Teleflex Incorporated completed its acquisition of BIOTRONIK's Vascular Intervention business, including the Pantera Lux drug-coated balloon, for an estimated cash payment of approximately EUR 760 million, significantly expanding its coronary and peripheral catheter-based therapy portfolio.

Drug-Coated Balloon Catheters Market Trends:

• Growing clinical shift from paclitaxel-based coatings toward sirolimus-eluting balloon platforms is improving drug retention and long-term vessel patency outcomes.

• Rising integration of AI-assisted intravascular imaging tools such as IVUS and OCT is enhancing lesion assessment and procedural precision during DCB interventions.

• Increasing physician preference for stent-free, leave-nothing-behind revascularization strategies is expanding DCB use in complex coronary and peripheral lesion subsets.

• Growing volume of outpatient and ambulatory surgical center-based endovascular procedures is widening access to DCB therapy for lower-risk femoropopliteal cases.

• Expanding strategic acquisitions and regional distribution partnerships among manufacturers are accelerating commercialization of next-generation DCB platforms across emerging markets.

U.S. Drug-Coated Balloon Catheters Market Outlook:

The U.S. Drug-Coated Balloon Catheters Market was valued at USD 498.60 Million in 2025 and is projected to reach USD 1,022.10 Million by 2035, growing at a CAGR of 8.30% during 2026–2035.

The U.S. Drug-Coated Balloons Market keeps growing owing to the presence of high prevalence of cardiovascular disease, well-developed infrastructure of catheterization laboratories, and increased use of DCB technology innovations. The use of paclitaxel-coated and sirolimus-coated balloons is growing in the treatment of in-stent restenosis and femoropopliteal peripheral artery disease at hospitals and medical centers. Expanded facilities for outpatient catheterizations are contributing to patient accessibility. Active participation in the market of medical device companies, clinical registries, and IDE trials results in the generation of evidence base, which builds confidence among physicians. In consequence, the U.S. is the largest market in North America and the center of DCB innovations and product development.

In February 2025, UPMC Heart and Vascular Institute began routinely using the AGENT drug-coated balloon for coronary in-stent restenosis following its FDA approval, integrating the device into clinical practice as an alternative to repeat stenting.

Drug-Coated Balloon Catheters Market Segment Analysis:

• By Type, Peripheral DCB dominated the Drug-Coated Balloon Catheters Market with a 71.40% share in 2025, while Coronary DCB is the fastest-growing type segment with a CAGR of 9.65% from 2026–2035.

• By End Use, Hospitals dominated the Drug-Coated Balloon Catheters Market with a 68.30% share in 2025, while Ambulatory Surgical Centers (ASCs) is the fastest-growing end-use segment with a CAGR of 10.15% from 2026–2035.

By Type, Peripheral DCB dominated the Drug-Coated Balloon Catheters Market, while Coronary DCB is the fastest-growing segment.

The Peripheral DCB segment was the leading contributor in the Drug-Coated Balloon Catheters Market in 2025. Peripheral DCB dominance is anchored in the rapidly rising global burden of peripheral artery disease, particularly femoropopliteal and below-the-knee lesions, where drug-coated balloons offer an effective, stent-free alternative that restores vessel patency while minimizing the risk of stent fracture and in-stent restenosis associated with permanent scaffolding in long, mobile peripheral vessel segments. Growing clinical evidence supporting sustained primary patency and low target-lesion revascularization rates with newer sirolimus-coated peripheral platforms continues to reinforce physician confidence and broaden routine use of peripheral DCB therapy across vascular surgery and interventional radiology practice.

The Coronary DCB segment is expected to witness strong growth during the forecast period 2026–2035. Growth is being driven by mounting real-world and randomized trial evidence demonstrating significantly lower rates of target lesion failure and target-vessel myocardial infarction with paclitaxel- and sirolimus-coated coronary balloons compared with conventional uncoated balloons in the treatment of in-stent restenosis and small-vessel coronary disease. Rapid clinical uptake following recent regulatory approvals, together with growing operator familiarity with a leave-nothing-behind treatment philosophy for complex coronary lesion subsets, is accelerating coronary DCB adoption.

By End Use, Hospitals dominated the Drug-Coated Balloon Catheters Market, while Ambulatory Surgical Centers (ASCs) is the fastest-growing segment.

The Hospitals segment dominated the Drug-Coated Balloon Catheters Market. Hospitals continue to perform the overwhelming majority of coronary and complex peripheral DCB procedures owing to their comprehensive catheterization laboratory infrastructure, availability of advanced intravascular imaging and hybrid operating capabilities, and on-site access to interventional cardiology, vascular surgery, and emergency care teams needed to manage complex or high-risk cases. Large hospital systems and academic medical centers are also the primary sites for early clinical adoption of newly approved DCB technologies, translating regulatory approvals into routine practice ahead of smaller outpatient facilities.

The Ambulatory Surgical Centers (ASC) Segment is anticipated to exhibit the highest growth rate during the forecast period 2026-2035. This growth is attributed to the general trend towards moving endovascular cases which pose lesser risk such as femoropopliteal peripheral DCB angioplasty from in-patient settings to out-patient settings where there will be shorter hospital stays, quicker patient recovery time and cost-effective treatment. The development of catheterization facilities within ASCs combined with the increasing reimbursement opportunities for vascular intervention in an out-patient setting allows for the delivery of DCB treatment outside the in-patient hospital setting.

Regional Analysis:

North America Drug-Coated Balloon Catheters Market Insights

The North America Drug-Coated Balloon Catheters Market held the largest regional revenue share of 44.50% in 2025, driven by the region's persistently high burden of cardiovascular and peripheral artery disease, extensive availability of advanced catheterization laboratory infrastructure, and strong presence of leading global device manufacturers. Robust clinical trial activity, favorable reimbursement pathways for interventional cardiology and vascular procedures, and rapid translation of newly approved DCB technologies into routine hospital and outpatient practice continue to reinforce the region's leadership position.

The United States accounted for 90.20% of the North America Drug-Coated Balloon Catheters Market in 2025, supported by a persistently high cardiovascular disease mortality burden, dense availability of catheterization laboratories, and swift clinical adoption of recently FDA-approved paclitaxel- and sirolimus-coated balloon platforms. Canada is contributing to regional growth through steady expansion of interventional cardiology capacity and growing adoption of minimally invasive peripheral vascular treatment protocols across its provincial healthcare systems.

Europe Drug-Coated Balloon Catheters Market Insights

Europe held a meaningful share of global revenue, supported by Drug-Coated Balloon Catheters Market in 2025, supported by a well-established interventional cardiology infrastructure, high prevalence of coronary and peripheral artery disease affecting tens of millions of people across the region, and strong physician familiarity with DCB-based treatment protocols developed over more than a decade of clinical use. Continued expansion of catheterization laboratory capacity and growing preference for stent-free revascularization in selected coronary and peripheral lesion subsets continue to support steady regional growth.

Germany represents one of the major markets in the region owing to the presence of high rates of peripheral vascular diseases and well-developed referral infrastructure for interventional cardiology and vascular surgery procedures. The UK and France are also actively participating in the regional market growth owing to increasing cases of acute coronary syndromes and usage of DCB as a treatment for in-stent restenosis in patients receiving interventional cardiology care.

Asia Pacific Drug-Coated Balloon Catheters Market Insights

The Asia Pacific Drug-Coated Balloon Catheters Market is expected to register the fastest CAGR of 10.20% during the forecast period 2026–2035, driven by the region's rapidly rising cardiovascular disease burden, expanding catheterization laboratory infrastructure, and growing government investment in cardiac care access across both urban and semi-urban healthcare systems. Rising physician awareness of vessel-preserving DCB treatment approaches, combined with increasing local manufacturing and technology transfer initiatives by global and regional players, is accelerating adoption across the region's major and emerging economies.

China led the market among the Asian Pacific countries in the Asia Pacific Drug-Coated Balloon Catheters Market in 2025, which was fueled by the huge patient base suffering from cardiovascular diseases in the country and the rise in the number of domestic approvals of drug-coated balloons containing sirolimus. The contribution of India towards the growth of the market has been noteworthy due to the increasing number of patients with cardiovascular diseases and the investment made in the healthcare sector by the government.

Latin America Drug-Coated Balloon Catheters Market Insights

The Latin America Drug-Coated Balloon Catheters Market is expanding steadily, supported by a substantial and sustained cardiovascular disease burden, improving catheterization laboratory infrastructure, and rising adoption of minimally invasive endovascular procedures across the region's major economies. Growing expansion of specialty cardiac centers and private healthcare providers continues to support broader access to advanced DCB-based vascular treatment.

Brazil is set to remain the leading Latin American market, supported by its substantial cardiovascular disease mortality burden and expanding network of interventional cardiology and vascular referral centers. Argentina and Mexico are also contributing to regional growth through rising catheterization laboratory investment and increasing adoption of DCB-based therapy for both coronary and peripheral vascular indications.

Middle East & Africa Drug-Coated Balloon Catheters Market Insights

The market in Middle East & Africa for Drug-Coated Balloon Catheters is experiencing continuous growth owing to the high incidence of cardiovascular risk factors like obesity, diabetes, and hypertension in the region along with investments in cardiac care infrastructure in important countries in the region. Increasing presence of global companies in the region and growing efforts for training of physicians are contributing to growing availability of advanced DCB technologies.

Saudi Arabia accounted for the maximum market share in the Middle East & Africa Drug-Coated Balloon Catheters Market during 2025 owing to considerable investments made by the country in its cardiac care infrastructure. The United Arab Emirates and South Africa are also supporting the growth of the market in the region through growing cardiac specialty centers and increasing demand for minimally invasive treatment of coronary and peripheral artery diseases.

Market Dynamics:

Growth Drivers: Rising cardiovascular and peripheral artery disease burden driving market growth

Rising global prevalence of cardiovascular and peripheral artery disease, growing physician preference for minimally invasive, stent-free revascularization strategies, and mounting clinical evidence demonstrating superior restenosis outcomes over conventional balloon angioplasty are among the primary drivers of the Drug-Coated Balloon Catheters Market. Drug-coated balloon catheters deliver targeted antiproliferative therapy directly to the vessel wall without leaving a permanent implant behind, making them an increasingly preferred option for managing in-stent restenosis, femoropopliteal peripheral artery disease, and selected complex coronary lesion subsets across hospital, specialty cardiac center, and outpatient interventional settings globally.

Growing volumes of catheterization laboratory procedures, expanding clinical adoption of sirolimus-based drug-eluting balloon platforms that improve drug retention and long-term patency compared with legacy paclitaxel coatings, and continued regulatory approvals widening the addressable indication base are further reinforcing sustained market expansion. Rising integration of AI-assisted intravascular imaging tools is also improving procedural precision and physician confidence, supporting broader clinical adoption of DCB technologies across both mature and emerging cardiovascular care markets.

Restraints: High device costs and procedural complication risks limiting market expansion

Among the foremost barriers to growth in the Drug-Coated Balloon Catheters Market is the relatively higher cost of the DCB products compared to the traditionally used uncoated balloon products, as well as the requirement of special catheterization equipment and trained professionals, restricting its adoption by low-budget healthcare facilities and in developing markets that lack established reimbursement systems for advanced angioplasty procedures. The longer process of regulatory approvals in leading markets is also likely to increase the development cost as well as restrict commercial access to newer versions of DCB products.

Another barrier to the adoption of DCB products includes the risks involved in the procedure, such as the occurrence of restenosis, vessel dissection, and non-uniform delivery of drug to the target area in cases involving complicated anatomy. Further concerns over the safety of certain paclitaxel-based coatings in peripheral applications have also restricted the adoption pace in selected regions.

Opportunities: Sirolimus-based technology innovation and emerging market expansion creating new growth avenues

The ongoing trend away from paclitaxel-coated products and towards newer sirolimus-eluting balloon technologies that offer better drug retention, greater patency rate and a relatively safer long-term safety profile would constitute an important growth driver in the market. Companies that develop the next-generation technology and systems for sustained release drug delivery and advanced coatings would be in a strong position to tap into the rising trend of DCBs with respect to safety and effectiveness among physicians and patients.

Market penetration into developing economies of Asia-Pacific, Latin America and the Middle East is another potential avenue of growth owing to increased investment in healthcare facilities and catheterization laboratories as well as rising emphasis by governments on improving cardiac care services in such nations. Development of DCB technology using artificial intelligence-based intravascular imaging and procedure guidance systems would further pave the way for new opportunities in the market.

Recent Developments:

• 2024: Boston Scientific launched the AGENT paclitaxel-coated balloon catheter, the first FDA-approved coronary drug-coated balloon in the U.S. for the treatment of coronary in-stent restenosis.

• 2025: ANVISA approved Cardionovum's Aperto over-the-wire (OTW) drug-coated balloon for commercial use in Brazil, enabling dialysis patients to access a therapy that prolongs arteriovenous fistula lifespan.

• 2025: BrosMed and Cordis entered a strategic collaboration to commercialize the VaSecure next-generation drug-coated balloon across China, strengthening distribution and clinical adoption.

• 2025: MicroPort Scientific Corporation received National Medical Products Administration (NMPA) approval in China for its Firelimus sirolimus-coated drug-coated balloon, supporting broader Asia Pacific commercialization.

• 2023: Cordis completed its acquisition of MedAlliance, adding the SELUTION SLR sustained sirolimus-release drug-eluting balloon platform to its portfolio.

Drug-Coated Balloon Catheters Market Key Players are:

• Boston Scientific Corporation

• Medtronic plc

• B. Braun SE

• Concept Medical Inc.

• Abbott

• Koninklijke Philips N.V.

• Teleflex Incorporated (BIOTRONIK)

• Translumina

• MicroPort Scientific Corporation

• Cardionovum GmbH

• iVascular S.L.U.

• Lepu Medical Technology

• Meril Life Sciences Pvt. Ltd.

• Cordis

• Acotec Scientific Holdings

• SMT (Sahajanand Medical Technologies)

• Bayer AG

• BrosMed Medical

Drug-Coated Balloon Catheters Market Report Scope: